ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
46 announcements
Astec LifeSciences responded to an NSE surveillance query on volume spurt. The company confirmed no developments requiring mandatory disclosure under LODR or PIT Regulations.
Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.
Astec LifeSciences replied to an NSE volume-spike surveillance notice, confirming full disclosure compliance. No undisclosed developments exist under Listing or PIT Regulations.
Astec LifeSciences has set record dates for the redemption of three Commercial Paper series, with each series maturing at a value of ₹25 Crore.
Astec LifeSciences held its 32nd AGM on July 31, 2026. The meeting approved financial statements, director re-appointment, and cost auditor remuneration.
Astec LifeSciences announced its Q1 FY27 financial results, reporting total income of ₹84.3 crore and an EBITDA of ₹0.1 crore.
Astec LifeSciences confirmed nil deviation in the utilization of proceeds from its listed Non-Convertible Debentures for the quarter ended 30th June, 2026.
Astec Lifesciences Ltd reported revenue from operations of ₹83.6 Cr (-8.2% YoY) and a net loss of ₹18.7 Cr for Q1 FY27.
Astec LifeSciences Ltd scheduled a board meeting on July 31, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.
Astec Lifesciences Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing lists promoters and public shareholders' stakes.
Astec LifeSciences scheduled its AGM for July 31, 2026. Agenda includes financial statement adoption, director re-appointment, and ratifying auditor remuneration of Rs. 0.015 Crore.
Astec LifeSciences submitted its FY 2025-26 Annual Report and AGM notice. The 32nd Annual General Meeting is scheduled for July 31, 2026.
Astec LifeSciences appointed five directors, including Vishal Sharma as Chairperson. Other appointees include Burjis N. Godrej and Arijit Mukherjee to strengthen leadership.
Astec Lifesciences Ltd announced the outcome of its Postal Ballot, with all resolutions passed by overwhelming majority. The results, including director appointments, were filed with stock exchanges.
Ms. Vijayalakshmi Iyer has resigned as General Manager – Human Resources at Astec LifeSciences Limited. This senior management departure is for pursuing new career opportunities.
Astec LifeSciences issued a postal ballot notice for director appointments and related party transactions. Proposed transaction limits with Godrej group entities total ₹405 Crore for FY2026-27.
Astec LifeSciences issued a postal ballot notice for director appointments and related party transactions. Shareholders can vote electronically from June 5 to July 4, 2026.
Astec LifeSciences Limited allotted 582 equity shares following the exercise of stock options under its ESOP scheme. The issuance marginally increases the company's total paid-up share capital.
Astec LifeSciences Limited allotted 582 equity shares under its ESOP scheme. This marginal capital increase reflects the ongoing exercise of employee stock options.
Astec LifeSciences Limited allotted 582 equity shares following the exercise of employee stock options. The company realized Rs.5,820 from this allotment at an exercise price of Rs.10.
Astec LifeSciences Limited successfully redeemed its listed Commercial Paper worth ₹25 Crore on maturity. The timely payment reinforces the company's financial discipline and debt servicing reliability.
Astec LifeSciences clarified to NSE that recent volume spurts are market-driven with no undisclosed developments. The company maintains full compliance with all SEBI disclosure regulations.
Astec LifeSciences submitted its Annual Secretarial Compliance Report for the financial year ended March 2026. The report details regulatory compliance status and past governance observations.
Astec LifeSciences Limited confirmed the timely redemption of ₹25 Crore worth of Commercial Papers. The payment was made upon maturity on May 22, 2026.
Astec LifeSciences notified shareholders regarding the mandatory transfer of unclaimed dividends and shares to the IEPF. This routine regulatory compliance follows the seven-year non-claim threshold.
Astec LifeSciences fixed June 2026 record dates for redeeming four Commercial Paper series. Investors should track these dates to ensure timely receipt of maturity payments.
Astec LifeSciences Limited has approved the grant of 1,142 stock options to an eligible grantee under its ESOP 2012 plan. The options have an exercise price of Rs.10 each and will vest over a three-year period. This move aligns employee interests with long-term shareholder value creation.
Astec LifeSciences Limited confirmed the timely redemption and payment of ₹25 Crore for its Commercial Papers (Series ASTEC-CP-186). The papers matured on April 29, 2026. This announcement demonstrates the company's adherence to its debt obligations and financial stability.
Astec LifeSciences Limited has fixed the record dates for the redemption of two Commercial Paper series maturing in May 2026. The total redemption amount is ₹50 Crore, split across two ₹25 Crore tranches listed on the NSE.
Astec LifeSciences Limited issued a compliance certificate for its 8.90% Unsecured Non-Convertible Debentures totalling ₹49 Crore. As the NCDs are unsecured, the company filed a nil security cover certificate for the quarter ended March 31, 2026.